The Food and Drug Administration (FDA) recently approved what may be the world's first "smart pill." Abilify MyCite, (aripiprazole) a "pill with a sensor that digitally tracks if patients have ingested their medication" was approved for sale and distribution by the FDA in mid-November. Now, a month after the drug's approval, several of the world's leading medical doctors are questioning the ethics surrounding the controversial drug.
Presumably using "compliance" with taking prescribed medicines as justification, the drug, "has an ingestible sensor embedded in the pill that records that the medication was taken." Abilify MyCite was "approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults." Abilify is a selective serotonin reuptake inhibitor (SSRI), a class of drugs which, by law, must contain the following black box warning label for consumers.